The opioid crisis has trained most people to associate dangerous opioid activity with prescription painkillers or illicit drugs. What it did not prepare them for was a product sold next to energy drinks at the gas station, legally, in 2026, that binds to the same brain receptors as morphine with significantly greater potency.
That product is kratom concentrate 7-OH, and the story of why it is still on shelves is equal parts regulatory history, political pressure, and industry strategy.
What the Science Says
Kratom, the plant, has been used in Southeast Asia for centuries. The leaves contain over 50 alkaloids, but two drive its pharmacological effects: mitragynine, the primary compound, and 7-hydroxymitragynine, a minor constituent that makes up less than 2% of the plant's natural alkaloid content. 7-OH demonstrates substantially greater mu-opioid receptor potency than kratom's primary alkaloid mitragynine, as well as classical opioids such as morphine.
That potency gap is the entire story. While raw kratom leaves have limited concentrations of both compounds, companies have begun to concentrate or synthetically produce 7-OH to create far stronger products. The result is a compound that the brain's opioid system cannot distinguish from pharmaceutical opioids, packaged as a supplement and marketed without the regulatory scrutiny those opioids require.
Kratom's compounds produce classic opioid-related effects such as sedation, nausea, constipation, physical dependence, withdrawal, and respiratory depression that may lead to death. The FDA has not approved any product containing kratom, mitragynine, or 7-OH.
Why It Stayed Legal This Long
The answer is not that the evidence was unclear. It is that the regulatory process failed to move faster than the market.
In 2016, the DEA published notice of its intent to place mitragynine and 7-OH in Schedule I on an emergency basis, which would have criminalized possession of kratom. However, after receiving numerous comments from members of Congress, advocacy groups, and others, DEA withdrew that notice.
That withdrawal had consequences that extended well past 2016. It signaled to the industry that sustained public pressure could block federal scheduling, and the kratom advocacy ecosystem grew accordingly. Meanwhile, the concentrated 7-OH market expanded quietly, operating in the regulatory gap that the failed scheduling attempt left open.
Kratom and its derivatives are not currently scheduled substances, and the FDA has not approved kratom, 7-OH, or mitragynine. The resulting patchwork of state-level rules created a situation where a product's legal status depends entirely on the zip code of the person buying it.
Where Things Stand Now
Federal regulators have finally moved with some urgency. The FDA is taking steps to protect Americans from dangerous, illegal opioids by recommending a scheduling action to control certain 7-OH products under the Controlled Substances Act, specifically targeting 7-OH as a concentrated byproduct of the kratom plant.
The language from federal health officials has grown notably direct. FDA Commissioner Dr. Marty Makary has called concentrated, synthetic 7-OH a potential fourth wave of the opioid epidemic.
The FDA's recommendation to schedule 7-OH will now go to the DEA, which oversees the final steps of the process, including issuing a formal proposal and opening a public comment period. Stateline That process takes time. In the meantime, the products remain available.
What This Means for People Seeking Treatment
The legal status of a substance has never been a reliable indicator of its danger, and 7-OH is a clear example of why. People who have developed dependence on concentrated 7-OH products are presenting clinically with the full profile of opioid use disorder. The withdrawal syndrome is severe. Tolerance builds quickly. And because these products have been sold as supplements rather than drugs, many people enter treatment genuinely unclear about the severity of what they are dealing with.
The FDA is particularly concerned with the growing market of 7-OH products that may be especially appealing to younger consumers, such as fruit-flavored gummies, which are sometimes disguised or marketed simply as kratom.
At Sunflower Recovery, treatment for kratom and 7-OH dependence follows the same evidence-based framework applied to opioid use disorder, because that is what the clinical evidence supports. That includes medically supervised detox, evaluation for medication-assisted treatment, and a step-down continuum of care that addresses the conditions that made these substances feel necessary in the first place. The goal is not just to stop the substance. It is to build a life that does not require it.
The regulatory gap that allowed 7-OH to reach this scale of harm is closing. The people caught in that gap deserve treatment that takes their situation seriously.
If you or someone you care about is struggling with kratom or 7-OH use, Sunflower Recovery's team is here to help. Call us today.